SELLAS Life Sciences Group Inc
RXK3
Company Profile
Business description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Contact
7 Times Square
Suite 2503
New YorkNY10036
USAT: +1 646 200-5278
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,181.60 | 29.90 | -0.32% |
| CAC 40 | 8,330.97 | 16.23 | -0.19% |
| DAX 40 | 25,286.24 | 134.42 | -0.53% |
| Dow JONES (US) | 49,149.63 | 42.36 | -0.09% |
| FTSE 100 | 10,184.35 | 47.00 | 0.46% |
| HKSE | 26,999.81 | 151.34 | 0.56% |
| NASDAQ | 23,471.75 | 238.13 | -1.00% |
| Nikkei 225 | 53,858.88 | 482.35 | -0.89% |
| NZX 50 Index | 13,698.24 | 59.47 | -0.43% |
| S&P 500 | 6,926.60 | 37.14 | -0.53% |
| S&P/ASX 200 | 8,854.50 | 26.50 | -0.30% |
| SSE Composite Index | 4,126.09 | 12.67 | -0.31% |